Format

Send to

Choose Destination
Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.353. [Epub ahead of print]

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network.

Author information

1
Wilhelminen Cancer Research Institute, Vienna, Austria.
2
Stem Cell Biology and Embryology Unit, Department of Development and Regeneration, Catholic University Leuven, Leuven, Belgium.
3
Department of Hematology, Lille University Hospital, Lille, France.
4
Department of Internal Medicine II, University Hospital of Wuerzburg, Wuerzburg, Germany.
5
Myeloma Unit, Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy.
6
Department of Hematology, University Hospital, University of Nantes, Nantes, France.
7
Centre de Recherches en Cancerologie de Toulouse CRCT, Institut National de la Sante et de la Recherche Medicale, Université Toulouse, Toulouse, France.
8
Division of Hematology, Citta della Salute e della Scienza, University of Torino, Torino, Italy.
9
Faculty of Medicine, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic.
10
Department of Haematology, Saint Antoine Hospital, University Pierre and Marie Curie, and INSERM UMRs 938, Paris, France.
11
a 'Seràgnoli' Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
12
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
13
Department of Hematology, Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona, Spain.
14
Department of Hematology, VU University Medical Center, Amsterdam, Netherlands.
15
Hospital Universitario de Salamanca, Instituto Biosanitario de Salamanca (IBSAL), Salamanca, Spain.
16
Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
17
Service d'Hématologie et Thérapie Cellulaire, PRC, and Inserm CIC1402, Hospital de la Miléterie, Poitiers, France.
18
National Center for Tumor Diseases, Heidelberg Medical University, Heidelberg, Germany.
19
Department of Hematology, Newcastle University, Newcastle, UK.
20
Myeloma Group, The Institute of Cancer Research ICR, London, UK.
21
Department of Hematology and Oncology, University of Tuebingen, Tuebingen, Germany.
22
Department of Hematology, St Olavs Hospital, and IKOM, NTNU, Trondheim, Norway.
23
Department of Medicine, Ankara University, Ankara, Turkey.
24
Department of Hematology Sahlgrenska Hospital, Gothenburg, Sweden.
25
Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany.
26
Department of Hematology, University Hospital of Liège, Liège, Belgium.
27
Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
28
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.

Abstract

During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drugs classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.Leukemia accepted article preview online, 18 December 2017. doi:10.1038/leu.2017.353.

PMID:
29251284
DOI:
10.1038/leu.2017.353
Free full text

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for ORBi (University of Liege)
Loading ...
Support Center